Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.

The effects of tuberculosis (TB) on the kinetics of CD4(+) T cells among HIV-infected individuals with early combination antiretroviral therapy (cART) after TB therapy initiation are poorly characterized. We conducted a case-control study with 15 HIV-TB-coinfected patients who initiated TB treatment and early cART, and 30 controls without TB who had similar CD4(+) T cell counts and viral loads at the time of starting cART. We compared the rate of CD4(+) T cell increase for 5 years after cART. The time to CD4(+) T cell increase >250 cells/mm(3) was significantly slower in HIV-TB-coinfected patients (p=0.015, by log rank test). HIV-TB-coinfected patients had significantly lower median CD4(+) T cell counts at 5 years after cART (p=0.048). The difference in CD4(+) T cell increase was observed only during the first 6 months after cART initiation (p=0.002). These data suggest that TB slows the rate of CD4(+) T cell recovery at an early period after cART. The effects of TB on the long-term immunity of HIV-infected patients should be further evaluated.

[1]  Anneke Grobler,et al.  Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.

[2]  Lerato Mohapi,et al.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.

[3]  D. Havlir,et al.  Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. , 2011, The Journal of infectious diseases.

[4]  A. Kiragga,et al.  Incident Tuberculosis during Antiretroviral Therapy Contributes to Suboptimal Immune Reconstitution in a Large Urban HIV Clinic in Sub-Saharan Africa , 2010, PloS one.

[5]  W. El-Sadr,et al.  Timing of initiation of antiretroviral drugs during tuberculosis therapy. , 2010, The New England journal of medicine.

[6]  C. Peloquin,et al.  Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Giulia Marchetti,et al.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Cole,et al.  Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence , 2008, AIDS.

[9]  F. Altice,et al.  Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners , 2007, HIV clinical trials.

[10]  M. Kozal,et al.  A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.

[11]  Roger Chou,et al.  Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses , 2006, The Lancet.

[12]  S. Karim.  Durban 2000 to Toronto 2006: the evolving challenges in implementing AIDS treatment in Africa. , 2006, AIDS.

[13]  M. Clerici,et al.  Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART , 2006, AIDS.

[14]  C. Dye,et al.  Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. , 2006, The Lancet. Infectious diseases.

[15]  John L. Johnson,et al.  Mycobacterium tuberculosis and human immunodeficiency virus type 1 interaction: Pathogenesis and disease modulation in dual infection , 2014 .

[16]  R. Weber,et al.  Persistent Apoptosis in HIV-1-Infected Individuals Receiving Potent Antiretroviral Therapy Is Associated With Poor Recovery of CD4 T Lymphocytes , 2004, Journal of acquired immune deficiency syndromes.

[17]  M. Aliyu,et al.  Tuberculosis and HIV disease: Two decades of a dual epidemic , 2003, Wiener Klinische Wochenschrift.

[18]  Jeffrey N. Martin,et al.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.

[19]  Caroline A Sabin,et al.  The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy , 2003, AIDS.

[20]  John L. Johnson,et al.  Increased Replication of HIV‐1 at Sites of Mycobacterium tuberculosis Infection: Potential Mechanisms of Viral Activation , 2001, Journal of acquired immune deficiency syndromes.

[21]  G. Vanham,et al.  T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB) , 2000, Clinical and experimental immunology.

[22]  Felipe García,et al.  Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection , 2000, AIDS.

[23]  John L. Johnson,et al.  Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda , 2000, AIDS.

[24]  C. Sabin,et al.  Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.

[25]  R. Weber,et al.  Highly active antiretroviral therapy during early HIV infection reverses T‐cell activation and maturation abnormalities , 1998 .

[26]  Rob J. De Boer,et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.

[27]  D. Weissman,et al.  Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. , 1996, Journal of immunology.

[28]  Dinakar,et al.  T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. , 1994, The Journal of clinical investigation.

[29]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[30]  R. Weber,et al.  Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. , 1998, AIDS.